- Published on
Pharmacology - Leflunomide
An inhibitory activity on activated T cells is responsible for the modification of the immune response that is the root cause of rheumatoid arthritis.
The mechanism of action involves the formation of a metabolite that leads to the inhibition of dihydrooratate dehydrogenase. This, in turn, leads to the inhibition of T-cell proliferation and a reduction in the production of autoantibodies by B cells.
Orally absorbed by the body. The metabolite is subjected to enterohepatic cycling, with a half-life period of approximately 18 days.
Use in clinical settings
Rheumatoid arthritis is a condition. The combination of methotrexate and this medication is particularly effective.
Adverse Effects
Two-fifths of patients experience diarrhea. There is a possibility of increased blood pressure and weight gain. It is possible for the long half-life to result in cumulative toxicity.
An inhibitory activity on activated T cells is responsible for the modification of the immune response that is the root cause of rheumatoid arthritis.
The mechanism of action involves the formation of a metabolite that leads to the inhibition of dihydrooratate dehydrogenase. This, in turn, leads to the inhibition of T-cell proliferation and a reduction in the production of autoantibodies by B cells.
Orally absorbed by the body. The metabolite is subjected to enterohepatic cycling, with a half-life period of approximately 18 days.
Use in clinical settings
Rheumatoid arthritis is a condition. The combination of methotrexate and this medication is particularly effective.
Adverse Effects
Two-fifths of patients experience diarrhea. There is a possibility of increased blood pressure and weight gain. It is possible for the long half-life to result in cumulative toxicity.
0 Comments
